Gold Mining News – Lifestyle
Home
Sample Page
Author:
Solid Biosciences Inc.
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
May 7, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
April 30, 2026
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
April 28, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
April 7, 2026
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 19, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
March 11, 2026